VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC) - Concepedia

Concepedia

Publication | Open Access

VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC)

DOI Full Paper Access

35

Citations

0

References

2024

Year

Dongsheng Yue, Wenxiang Wang, Haibo Liu, Qian Chen, C. Chen, Lei Liu, P. Zhang, Genming Zhao, Fan Yang, Guang Han,

Annals of Oncology

No additional data available for this publication yet. Check back later!